HANCHORBIO ANNOUNCES TAIWAN FDA IND APPROVAL FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES

1.Why was HanchorBio founded? 2.When was HanchorBio established, and what is its founding mission?3. What research achievements or fundraising successes has HanchorBio accomplished so far? 4.What is HanchorBio’s vision? 5.In the fields of biotechnology and healthcare, what contributions can HanchorBio make to society? 6.What are the key differences and advantages between HanchorBio’s drug candidates and traditional therapies? What is the core technology? 7.What is FBDB™? What makes it special, and how does it support research and development? 8.What is the expected scale or extent of the beneficiaries? For such multi-target biologics designed to reactivate the immune system against diseases, can this mechanism be applied to other diseases or medical fields?